441 related articles for article (PubMed ID: 28206954)
1. RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA.
Giannopoulou L; Chebouti I; Pavlakis K; Kasimir-Bauer S; Lianidou ES
Oncotarget; 2017 Mar; 8(13):21429-21443. PubMed ID: 28206954
[TBL] [Abstract][Full Text] [Related]
2. Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer.
Bondurant AE; Huang Z; Whitaker RS; Simel LR; Berchuck A; Murphy SK
Gynecol Oncol; 2011 Dec; 123(3):581-7. PubMed ID: 21955482
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients.
Balgkouranidou I; Matthaios D; Karayiannakis A; Bolanaki H; Michailidis P; Xenidis N; Amarantidis K; Chelis L; Trypsianis G; Chatzaki E; Lianidou ES; Kakolyris S
Mutat Res; 2015 Aug; 778():46-51. PubMed ID: 26073472
[TBL] [Abstract][Full Text] [Related]
4. ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer.
Giannopoulou L; Mastoraki S; Buderath P; Strati A; Pavlakis K; Kasimir-Bauer S; Lianidou ES
Gynecol Oncol; 2018 Aug; 150(2):355-360. PubMed ID: 29807696
[TBL] [Abstract][Full Text] [Related]
5. Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas.
Choi YL; Kang SY; Shin YK; Choi JS; Kim SH; Lee SJ; Bae DS; Ahn G
Virchows Arch; 2006 Mar; 448(3):331-6. PubMed ID: 16315018
[TBL] [Abstract][Full Text] [Related]
6. [Hypermethylation of promoter region of RASSF1A gene in ovarian malignant epithelial tumors].
Ma L; Zhang JH; Liu FR; Zhang X
Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):657-9. PubMed ID: 16438885
[TBL] [Abstract][Full Text] [Related]
7. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
[TBL] [Abstract][Full Text] [Related]
8. Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer.
Spitzwieser M; Holzweber E; Pfeiler G; Hacker S; Cichna-Markl M
Breast Cancer Res; 2015 Sep; 17(1):125. PubMed ID: 26370119
[TBL] [Abstract][Full Text] [Related]
9. Methylation of RASSF1A gene promoter and the correlation with DNMT1 expression that may contribute to esophageal squamous cell carcinoma.
Du Z; Ma K; Sun X; Li A; Wang H; Zhang L; Lin F; Feng X; Song J
World J Surg Oncol; 2015 Apr; 13():141. PubMed ID: 25886188
[TBL] [Abstract][Full Text] [Related]
10. [Detection of circulating hypermethylated tumor-specific RASSF1A DNA in ovarian cancer patients].
Ma L; Liu FR; Zhang SL
Zhonghua Bing Li Xue Za Zhi; 2005 Dec; 34(12):785-7. PubMed ID: 16545186
[TBL] [Abstract][Full Text] [Related]
11. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
12. SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer.
Balgkouranidou I; Chimonidou M; Milaki G; Tsaroucha E; Kakolyris S; Georgoulias V; Lianidou E
Clin Chem Lab Med; 2016 Aug; 54(8):1385-93. PubMed ID: 26741346
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation markers and serum α-fetoprotein level are prognostic factors in hepatocellular carcinoma.
Lin JC; Wu YC; Wu CC; Shih PY; Wang WY; Chien YC
Ann Hepatol; 2015; 14(4):494-504. PubMed ID: 26019036
[TBL] [Abstract][Full Text] [Related]
14. HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival.
Davidson B; Holth A; Hellesylt E; Hadar R; Katz B; Tropé CG; Reich R
Hum Pathol; 2016 Feb; 48():95-101. PubMed ID: 26640230
[TBL] [Abstract][Full Text] [Related]
15.
Valle BL; Rodriguez-Torres S; Kuhn E; Díaz-Montes T; Parrilla-Castellar E; Lawson FP; Folawiyo O; Ili-Gangas C; Brebi-Mieville P; Eshleman JR; Herman J; Shih IM; Sidransky D; Guerrero-Preston R
Cancer Prev Res (Phila); 2020 Sep; 13(9):783-794. PubMed ID: 32581010
[TBL] [Abstract][Full Text] [Related]
16. [Methylation of the promoter region of the RASSF1A gene, a candidate tumor suppressor, in primary epithelial tumors].
Loginov VI; Maliukova AV; Seregin IuA; Khodyrev DS; Kazubskaia TP; Ermilova VD; Gar'kavtseva RF; Kiselev LL; Zabarovskiĭ ER; Braga EA
Mol Biol (Mosk); 2004; 38(4):654-67. PubMed ID: 15456137
[TBL] [Abstract][Full Text] [Related]
17. Hypermethylation-modulated downregulation of RASSF1A expression is associated with the progression of esophageal cancer.
Mao WM; Li P; Zheng QQ; Wang CC; Ge MH; Hu FJ; Fang XH; Dong ZM; Ling ZQ
Arch Med Res; 2011 Apr; 42(3):182-8. PubMed ID: 21722812
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological implications of inactivation of RASSF1A in serous epithelial ovarian cancers.
Ma L; Guo Q; Ma Y; Liu FR; Shen XY
Eur J Gynaecol Oncol; 2009; 30(4):370-4. PubMed ID: 19761124
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer.
Montavon C; Gloss BS; Warton K; Barton CA; Statham AL; Scurry JP; Tabor B; Nguyen TV; Qu W; Samimi G; Hacker NF; Sutherland RL; Clark SJ; O'Brien PM
Gynecol Oncol; 2012 Mar; 124(3):582-8. PubMed ID: 22115852
[TBL] [Abstract][Full Text] [Related]
20. Promoter Methylation of RASSF1A Gene in Egyptian Patients with Ovarian Cancer.
Rezk NA; Mohamed RH; Alnemr AA; Harira M
Appl Biochem Biotechnol; 2018 May; 185(1):153-162. PubMed ID: 29098560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
